119 related articles for article (PubMed ID: 2480854)
1. Arabinofuranosyl-5-azacytosine: activity against human tumors in athymic mice.
Wallace RE; Lindh D; Durr FE
Cancer Chemother Pharmacol; 1989; 25(2):117-23. PubMed ID: 2480854
[TBL] [Abstract][Full Text] [Related]
2. Arabinofuranosyl-5-azacytosine: antitumor and cytotoxic properties.
Dalal M; Plowman J; Breitman TR; Schuller HM; del Campo AA; Vistica DT; Driscoll JS; Cooney DA; Johns DG
Cancer Res; 1986 Feb; 46(2):831-8. PubMed ID: 2416433
[TBL] [Abstract][Full Text] [Related]
3. Comparison of the activity of arabinosyl-5-azacytosine, arabinosyl cytosine, and 5-azacytidine against intracerebrally implanted L1210 leukemia.
Driscoll JS; Johns DG; Plowman J
Invest New Drugs; 1985; 3(4):331-4. PubMed ID: 2417984
[TBL] [Abstract][Full Text] [Related]
4. A comparison of the lethal effects in culture of cytosine arabinoside and arabinofuranosyl-5-azacytosine acting on the blast cells fo acute myeloblastic leukemia.
Yang GS; McCulloch EA
Hematol Pathol; 1992; 6(3):125-30. PubMed ID: 1385380
[TBL] [Abstract][Full Text] [Related]
5. Cellular metabolism of 1-beta-D-arabinofuranosyl-5-azacytosine and incorporation into DNA and RNA of human lymphoid CEM/0 and CEM/dCk(-) cells.
Avramis VI; Powell WC; Mecum RA
Cancer Chemother Pharmacol; 1989; 25(1):19-24. PubMed ID: 2480187
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of a novel nucleoside, 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine (CNDAC) against murine and human tumors.
Tanaka M; Matsuda A; Terao T; Sasaki T
Cancer Lett; 1992 May; 64(1):67-74. PubMed ID: 1596880
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and antitumor activity of 5-azacytosine arabinoside.
Beisler JA; Abbasi MM; Driscoll JS
J Med Chem; 1979 Oct; 22(10):1230-4. PubMed ID: 92567
[TBL] [Abstract][Full Text] [Related]
8. Preclinical antitumor activity of 4'-thio-beta-D-arabinofuranosylcytosine (4'-thio-ara-C).
Waud WR; Gilbert KS; Shepherd RV; Montgomery JA; Secrist JA
Cancer Chemother Pharmacol; 2003 May; 51(5):422-6. PubMed ID: 12679884
[TBL] [Abstract][Full Text] [Related]
9. Antitumor activity of 2'-deoxy-2'-methylidenecytidine, a new 2'-deoxycytidine derivative.
Yamagami K; Fujii A; Arita M; Okumoto T; Sakata S; Matsuda A; Ueda T; Sasaki T
Cancer Res; 1991 May; 51(9):2319-23. PubMed ID: 2015596
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamic and DNA methylation studies of high-dose 1-beta-D-arabinofuranosyl cytosine before and after in vivo 5-azacytidine treatment in pediatric patients with refractory acute lymphocytic leukemia.
Avramis VI; Mecum RA; Nyce J; Steele DA; Holcenberg JS
Cancer Chemother Pharmacol; 1989; 24(4):203-10. PubMed ID: 2473850
[TBL] [Abstract][Full Text] [Related]
11. In vitro sensitivity of various human tumors to 1-beta-D-arabinofuranosylcytosine and N4-behenoyl-1-beta-D-arabinofuranosylcytosine.
Maehara Y; Kusumoto T; Kusumoto H; Anai H; Sugimachi K
Chemotherapy; 1989; 35(3):181-6. PubMed ID: 2766858
[TBL] [Abstract][Full Text] [Related]
12. Antitumor activity and cross-resistance of carmethizole hydrochloride in preclinical models in mice.
Waud WR; Plowman J; Harrison SD; Dykes DJ; Anderson WK; Griswold DP
Cancer Chemother Pharmacol; 1992; 30(4):261-6. PubMed ID: 1322803
[TBL] [Abstract][Full Text] [Related]
13. [Antitumor activity of a novel analog of cytarabine, 4-amino-1-beta-D-arabinofuranosyl-2(1H)-pyrimidinone 5'-(sodium octadecyl phosphate) monohydrate (YNK01)].
Nagahata T; Shibasaki C; Ishii T; Uchida T; Arakawa M; Kusama K; Ekimoto H; Takahashi K
Gan To Kagaku Ryoho; 1990 Aug; 17(8 Pt 1):1437-45. PubMed ID: 2389942
[TBL] [Abstract][Full Text] [Related]
14. Antineoplastic activity of conjugates of lipids and 1-beta-D-arabinofuranosylcytosine.
Berdel WE; Danhauser S; Schick HD; Hong CI; West CR; Fromm M; Fink U; Reichert A; Rastetter J
Lipids; 1987 Nov; 22(11):943-6. PubMed ID: 3444389
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of troxacitabine (Troxatyl) against anthracycline-resistant human xenografts.
Gourdeau H; Genne P; Kadhim S; Bibeau L; Duchamp O; Ouellet F; deMuys JM; Bouffard DY; Attardo G
Cancer Chemother Pharmacol; 2002 Dec; 50(6):490-6. PubMed ID: 12451476
[TBL] [Abstract][Full Text] [Related]
16. [Antitumor effects of Behenoyl-ara-C (BH-AC) in combination with Idarubicin (IDA) in P 388 leukemic cell bearing mice].
Watanabe A; Kuriyama H; Kiyota T
Gan To Kagaku Ryoho; 1996 Feb; 23(3):291-6. PubMed ID: 8712821
[TBL] [Abstract][Full Text] [Related]
17. Therapeutic activity of a thioether-lipid conjugate of 1-beta-D-arabinofuranosylcytosine in human colorectal cancer xenografts.
Herrmann R; Berdel WE
Cancer Res; 1992 Apr; 52(7):1865-7. PubMed ID: 1551115
[TBL] [Abstract][Full Text] [Related]
18. Phase I and pharmacological trial of fazarabine (Ara-AC) with granulocyte colony-stimulating factor.
Goldberg RM; Reid JM; Ames MM; Sloan JA; Rubin J; Erlichman C; Kuffel MJ; Fitch TR
Clin Cancer Res; 1997 Dec; 3(12 Pt 1):2363-70. PubMed ID: 9815635
[TBL] [Abstract][Full Text] [Related]
19. Sequence-dependent interaction of 5-fluorouracil and arabinosyl-5-azacytosine or 1-beta-D-arabinofuranosylcytosine.
Grem JL; Allegra CJ
Biochem Pharmacol; 1991 Jul; 42(2):409-18. PubMed ID: 1713459
[TBL] [Abstract][Full Text] [Related]
20. Cytotoxic liponucleotide analogs. II. Antitumor activity of CDP-diacylglycerol analogs containing the cytosine arabinoside moiety.
Turcotte JG; Srivastava SP; Steim JM; Calabresi P; Tibbetts LM; Chu MY
Biochim Biophys Acta; 1980 Sep; 619(3):619-31. PubMed ID: 7459369
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
